HCA
INDV icon

Harbor Capital Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Harbor Capital Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,033
Closed -$37K – 1358
2025
Q4 		$37K Buy
1,033
+781
+310% +$23.8K ﹤0.01% 730
2025
Q3 		$6K Buy
+252
New +$5.27K ﹤0.01% 1110

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Harbor Capital Advisors's INDV Position: Q1 2026 in Review

Harbor Capital Advisors sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 1,033 shares — an estimated $37K sold.

Harbor Capital Advisors first reported a position in INDV in Q3 2025 and held it in 2 quarters. The position peaked at $37K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Harbor Capital Advisors reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 1,033 Indivior Pharmaceuticals shares in Q1 2026, an estimated $37K.
  • Harbor Capital Advisors first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Harbor Capital Advisors's Indivior Pharmaceuticals position peaked at $37K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.